Trial Profile
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jan 2024
Price :
$35
*
At a glance
- Drugs SEL 24 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Acronyms DIAMOND; DIAMOND-01
- Sponsors Menarini; Menarini Ricerche
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 24 Mar 2023 According to Ryvu media release, updates from this study are expected in 2023.
- 23 Feb 2023 The trial has been completed in Poland, according to European Clinical Trials Database record.